Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4920
Peer-review started: March 16, 2023
First decision: May 8, 2023
Revised: May 10, 2023
Accepted: June 26, 2023
Article in press: June 26, 2023
Published online: July 16, 2023
Processing time: 110 Days and 17.1 Hours
Percutaneous transluminal coronary angioplasty, while an effective intervention, can frequently lead to acute occlusion with severe consequences. Although clinical trials have demonstrated the efficacy of drug-coated balloons (DCB) in treating acute coronary artery occlusion and in preventing restenosis, there has been limited exploration on the use of DCB in treating de novo lesions in large vessels. Currently, DCB are only recommended for patients with small vessel lesions and in-stent restenosis lesions, those at high risk of bleeding, and other special groups of patients.
This report presents a case of successful drug-coated balloon treatment of de novo lesions in large coronary vessels. Postoperatively, the patient demonstrated favorable recovery, with subsequent examination results revealing no significant differences from the previous examination.
The successful treatment of the patient in our case highlights the potential of DCB in the treatment of de novo lesions in large coronary vessels.
Core Tip: Drug-coated balloons (DCB) are currently only recommended for patients with small vessel lesions and in-stent restenosis lesions, those at high risk of bleeding, and other special groups of patients. This report presents a case of successful drug-coated balloon treatment of de novo lesions in large coronary vessels. The successful treatment of the patient in our case highlights the potential of DCB in the treatment of de novo lesions in large coronary vessels.